Celldex Therapeutics Stock
Price
Target price
€37.00
€37.00
0.550%
0.2
0.550%
€56.62
15.05.24 / Tradegate
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Celldex Therapeutics Stock
Celldex Therapeutics gained 0.550% compared to yesterday.
We see a rather positive sentiment for Celldex Therapeutics with 11 Buy predictions and 1 Sell predictions.
With a target price of 56 € there is a hugely positive potential of 51.35% for Celldex Therapeutics compared to the current price of 37.0 €.
So far the community has only identified positive things for Celldex Therapeutics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | 0.550% | -3.646% | 1.648% | 20.915% | 2.210% | 64.591% | 596.798% |
| Vaxart Inc. | -1.060% | 34.046% | 7.995% | -30.290% | 70.287% | -83.415% | - |
| Larimar Therapeutics Inc. | -6.940% | -4.965% | 3.077% | 101.807% | 64.216% | -39.091% | -74.494% |
| Jaguar Health Inc. | -7.220% | -11.604% | 57.992% | -61.728% | 58.411% | -99.895% | - |
Comments
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
